By Conjoint Professor David goldstein

Journal articles

Chiorean EG; Von Hoff DD; Tabernero J; El-Maraghi R; Wee Ma W; Reni M; Harris M; Whorf R; Liu H; Shiansong Li J; Manax V; Romano A; Lu B; Goldstein D, 2016, 'Erratum: Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer', British Journal of Cancer, 115, pp. e13 - e13, http://dx.doi.org/10.1038/bjc.2016.306

Pothula SP; Xu Z; Goldstein D; Pirola RC; Wilson JS; Apte MV, 2016, 'Key role of pancreatic stellate cells in pancreatic cancer', Cancer Letters, 381, pp. 194 - 200, http://dx.doi.org/10.1016/j.canlet.2015.10.035

Sharbeen G; Youkhana J; McCarroll J; Akerman A; Goldstein D; Phillips P, 2016, 'MutY-Homolog modulates pancreatic cancer cell survival and chemoresistance', Pancreatology, 16, pp. S5 - S5, http://dx.doi.org/10.1016/j.pan.2016.05.024

Oar AJ; Wong W; Chen C; Haghighi KS; Thompson S; Goldstein D, 2016, 'Stereotactic body hypofractionated radiotherapy for inoperable pancreatic cancer, with or without metastases', Hepato Pancreato Biliary, 18, pp. e359, http://dx.doi.org/10.1016/j.hpb.2016.02.932

Casali PG; Le Cesne A; Velasco AP; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Adenis A; Hartmann JT; Duffaud F; Goldstein D; Broto JM; Gronchi A; Dei Tos AP; Marréaud S; Van Der Graaf WTA; Zalcberg JR; Litière S; Blay JY, 2015, 'Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas', Journal of Clinical Oncology, 33, pp. 4276 - 4283, http://dx.doi.org/10.1200/JCO.2015.62.4304

Donskov F; Michaelson MD; Puzanov I; Davis MP; Bjarnason GA; Motzer RJ; Goldstein D; Lin X; Cohen DP; Wiltshire R; Rini BI, 2015, 'Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients', British Journal of Cancer, 113, pp. 1571 - 1580, http://dx.doi.org/10.1038/bjc.2015.368

Chandrasegaram MD; Goldstein D; Simes J; Gebski V; Kench JG; Gill AJ; Samra JS; Merrett ND; Richardson AJ; Barbour AP; Fawcett J; Grimison PS; Christophi C; Padbury R; Haghighi KS; Chen JW; Nikfarjam M; O'Rourke N; Spry N, 2015, 'Meta-analysis of radical resection rates and margin assessment in pancreatic cancer', British Journal of Surgery, 102, pp. 1459 - 1472, http://dx.doi.org/10.1002/bjs.9892

Stein A; Arnold D; Bridgewater J; Goldstein D; Jensen LH; Klümpen HJ; Lohse AW; Nashan B; Primrose J; Schrum S; Shannon J; Vettorazzi E; Wege H, 2015, 'Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial', BMC Cancer, 15, pp. 564, http://dx.doi.org/10.1186/s12885-015-1498-0

Jaeger U; Trneny M; Melzer H; Praxmarer M; Nawarawong W; Yehuda DB; Goldstein D; Mihaljevic B; Ilhan O; Ballova V; Hedenus M; Hsiao LT; Au WY; Burgstaller S; Weidinger G; Keil F; Dittrich C; Skrabs C; Klingler A; Chott A; Fridrik MA; Greil R, 2015, 'Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: Results of the randomized NHL13 trial', Haematologica, 100, pp. 955 - 963, http://dx.doi.org/10.3324/haematol.2015.125344

Apte MV; Xu Z; Pothula S; Goldstein D; Pirola RC; Wilson JS, 2015, 'Pancreatic cancer: The microenvironment needs attention too!', Pancreatology, 15, pp. S32 - S38, http://dx.doi.org/10.1016/j.pan.2015.02.013

Davis ID; Long A; Yip S; Espinoza D; Thompson JF; Kichenadasse G; Harrison M; Lowenthal RM; Pavlakis N; Azad A; Kannourakis G; Steer C; Goldstein D; Shapiro J; Harvie R; Jovanovic L; Hudson AL; Nelson CC; Stockler MR; Martin A, 2015, 'EVERSUN: A phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinoma', Annals of Oncology, 26, pp. 1118 - 1123, http://dx.doi.org/10.1093/annonc/mdv078

Sandler C; Goldstein D; Horsfield S; Bennett BK; Friedlander M; Bastick PA; Lewis CR; Segelov E; Boyle FM; Chin MTM; Barry BK; Webber K; Lloyd AR, 2015, 'TOPS: A randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue.', Journal of Clinical Oncology, 33, pp. 9571 - 9571, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.9571

Pantaleo MA; Lolli C; Nannini M; Astolfi A; Indio V; Saponara M; Urbini M; La Rovere S; Gill A; Goldstein D; Ceccarelli C; Santini D; Rossi G; Fiorentino M; Di Scioscio V; Fusaroli P; Mandrioli A; Gatto L; Catena F; Basso U; Ercolani G; Pinna AD; Biasco G, 2015, 'Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations', Genetics in Medicine, 17, pp. 391 - 395, http://dx.doi.org/10.1038/gim.2014.115

Lee CK; Goldstein D; Gibbs E; Joensuu H; Zalcberg J; Verweij J; Casali PG; Maki RG; Cioffi A; McArthur G; Lord SJ; Yip D; Kanjanapan Y; Rutkowski P, 2015, 'Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib', European Journal of Cancer, 51, pp. 852 - 860, http://dx.doi.org/10.1016/j.ejca.2015.02.015

Tebbutt N; Kotasek D; Burris HA; Schwartzberg LS; Hurwitz H; Stephenson J; Warner DJ; Chen L; Hsu CP; Goldstein D, 2015, 'Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer', Cancer Chemotherapy and Pharmacology, 75, pp. 993 - 1004, http://dx.doi.org/10.1007/s00280-015-2694-y

Sharbeen G; McCarroll J; Goldstein D; Phillips PA, 2015, 'Exploiting Base Excision Repair to Improve Therapeutic Approaches for Pancreatic Cancer', Frontiers in Nutrition, 2, pp. 10, http://dx.doi.org/10.3389/fnut.2015.00010

Sze M; Butow P; Bell M; Vaccaro L; Dong S; Eisenbruch M; Jefford M; Girgis A; King M; McGrane J; Ng W; Asghari R; Parente P; Liauw W; Goldstein D; Psycho-oncology Co-operative Research Group Culturally and Linguistically Diverse (CALD) TEAM , 2015, 'Migrant health in cancer: outcome disparities and the determinant role of migrant-specific variables', Oncologist, http://dx.doi.org/10.1634/theoncologist.2014-0274

Chan DL; Goldstein D; Zalcberg JR, 2015, 'Neuroendocrine tumours - Models for rare tumour management', Cancer Forum, 39, pp. 13 - 16

Goldstein D; El-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Tabernero J; Teixeira L; Tortora G; Van Laethem JL; Young R; Penenberg DN; Lu B; Romano A; Von Hoff DD, 2015, 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: Long-term survival from a phase III trial', Journal of the National Cancer Institute, 107, http://dx.doi.org/10.1093/jnci/dju413

Murphy C; Sabesan S; Steer C; Yates P; Booms A; Jones V; Simpson A; Clarke K; Eek R; Ashley D; Goldstein D; Packer C; Tuthill F; Boyce A; Underhill C, 2015, 'Oncology service initiatives and research in regional Australia', Australian Journal of Rural Health, 23, pp. 40 - 48, http://dx.doi.org/10.1111/ajr.12173

Wang X; Batty KM; Crowe PJ; Goldstein D; Yang JL, 2015, 'The Potential of panHER Inhibition in Cancer', Frontiers in Oncology, 5, pp. 2, http://dx.doi.org/10.3389/fonc.2015.00002

Pavlakis N; Sjoquist KM; Tsobanis E; Martin A; Kang Y-K; Bang Y-J; O'Callaghan CJ; Tebbutt NC; Rha SY; Lee J; Cho JY; Lipton LR; Burnell MJ; Alcindor T; Strickland A; Wong M; Kim JW; Simes J; Zalcberg JR; Goldstein D, 2015, 'INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced oesophagogastric cancer (AOGC)—A study by the Australasian Gastrointestinal Trials Group (AGITG), first results.', Journal of Clinical Oncology, 33, pp. 9 - 9, http://dx.doi.org/10.1200/jco.2015.33.3_suppl.9

Vernerey D; Hammel P; Paget-Bailly S; Huguet F; Van Laethem JL; Goldstein D; Glimelius B; Artru P; Moore MJ; André T; Mineur L; Chibaudel B; Louvet C; Bonnetain F, 2015, 'Prognosis model for overall survival in locally advanced unresecable pancreatic carcinoma: An ancillary study of the LAP 07 trial.', Journal of Clinical Oncology, 33, pp. 235 - 235, http://dx.doi.org/10.1200/jco.2015.33.3_suppl.235

Kunzmann V; Ramanathan RK; Goldstein D; Penenberg DN; Ferrara S; Lu B; Von Hoff DD, 2015, 'Tumor reduction in pancreatic versus metastatic sites in a randomized phase III study (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.', JOURNAL OF CLINICAL ONCOLOGY, 33, http://dx.doi.org/10.1200/jco.2015.33.3_suppl.382

Tabernero J; Gabrielachiorean E; Infante JR; Hingorani SR; Ganju V; Weekes C; Scheithauer W; Ramanathan RK; Goldstein D; Penenberg DN; Romano A; Ferrara S; Von Hoff DD, 2015, 'Prognostic factorsofsurvival inarandomizedphaseIIItrial (MPACT)of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer', Oncologist, 20, pp. 143 - 150, http://dx.doi.org/10.1634/theoncologist.2014-0394

Vajdic CM; Goldstein D, 2015, 'Cancer of unknown primary site', Australian Family Physician, 44, pp. 640 - 643

Burmeister EA; O'Connell DL; Beesley VL; Goldstein D; Gooden HM; Janda M; Jordan SJ; Merrett ND; Payne ME; Wyld D; Neale RE, 2015, 'Describing patterns of care in pancreatic cancer a population-based study', Pancreas, 44, pp. 1259 - 1265, http://dx.doi.org/10.1097/MPA.0000000000000384

McCarroll JA; Sharbeen G; Liu J; Youkhana J; Goldstein D; McCarthy N; Limbri LF; Dischl D; Ceyhan GO; Erkan M; Johns AL; Biankin AV; Kavallaris M; Phillips PA; Johns A, 2015, 'βIII-Tubulin: A novel mediator of chemoresistance and metastases in pancreatic cancer', Oncotarget, 6, pp. 2235 - 2249, http://dx.doi.org/10.18632/oncotarget.2946

Goldstein D; Fawcett J; Bridgewater J; Choti M; Wilson K; Gebski V; Aiken C; Eminton Z; Falk S; Stanton L; Primrose J, 2015, '2044 Feasibility of trials to assess safety and toxicity of peri-operative and post-operative adjuvant therapy for hepatic metastases from colorectal cancer', European Journal of Cancer, 51, pp. s343, http://dx.doi.org/10.1016/s0959-8049(16)30967-4

Neale R; Burmeister E; O'Connell D; Beesley V; Goldstein D; Gooden H; Janda M; Jordan S; Merrett N; Payne M; Wyld D, 2015, 'Describing patterns of care in pancreatic cancer – A population-based study', Pancreatology, 15, pp. S83 - S83, http://dx.doi.org/10.1016/j.pan.2015.05.306

Burmeister E; Jordan S; O'Connell D; Beesley V; Goldstein D; Gooden H; Janda M; Merrett N; Wyld D; Neale R, 2015, 'Determinants of attempted resection for patients with non-metastatic pancreatic cancer', Pancreatology, 15, pp. S84 - S85, http://dx.doi.org/10.1016/j.pan.2015.05.312

Neale R; Waterhouse M; Burmeister E; Ballard E; O'Connell D; Beesley V; Goldstein D; Gooden H; Janda M; Jordan S; Merrett N; Payne M; Wyld D, 2015, 'Determinants of outcomes following resection for pancreatic cancer – An Australian population-based study', Pancreatology, 15, pp. S85 - S85, http://dx.doi.org/10.1016/j.pan.2015.05.313

Pavlakis N; Sjoquist KM; Tsobanis E; Martin AJ; Kang Y-K; Bang Y-J; O'Callaghan CJ; Tebbutt NC; Rha SY; Lee J; Cho JY; Lipton LR; Burnell MJ; Alcindor T; Strickland A; Kim JW; Yip S; Simes J; Zalcberg JR; Goldstein D, 2015, 'LBA-06 INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib (REG) in refractory advanced oesophagogastric cancer (AOGC) - A study by the Australasian Gastrointestinal Trials Group (AGITG): Final overall and subgroup results', Annals of Oncology, 26, pp. iv119, http://dx.doi.org/10.1093/annonc/mdv262.06

Tempero M; Cardin D; Biankin A; Goldstein D; Moore M; O'Reilly E; Philip P; Riess H; Macarulla T; Yung L; Li M; Lu B, 2015, 'P-185 Randomized phase III trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) vs Gem alone as adjuvant therapy for patients with resected pancreatic cancer: APACT', Annals of Oncology, 26, pp. iv54, http://dx.doi.org/10.1093/annonc/mdv233.185

Vernerey D; Goldstein D; Huguet F; Paget-Bailly S; Van Laethem J-L; Glimelius B; Artru P; Moore MJ; André T; Mineur L; Chibaudel B; Louvet C; Hammel P; Bonnetain F, 2015, 'Prognostic score and nomogram to predict overall survival in locally advanced pancreatic cancer', Pancreatology, 15, pp. S107 - S107, http://dx.doi.org/10.1016/j.pan.2015.05.383

Tempero M; Cardin D; Biankin AV; Goldstein D; Moore M; O'Reilly E; Philip P; Riess H; Macarulla T; Yung L; Li M; Lu B, 2015, 'Tu1953 Nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Resected Pancreatic Cancer in a Phase III Trial (APACT)', Gastroenterology, 148, pp. S - 944, http://dx.doi.org/10.1016/s0016-5085(15)33220-0

Park SB; Kwok JB; Loy CT; Friedlander ML; Lin CSY; Krishnan AV; Lewis CR; Kiernan MC; goldstein D, 2014, 'Paclitaxel-induced neuropathy: Potential association of MAPT and GSK3B genotypes', BMC Cancer, 14, pp. 993, http://dx.doi.org/10.1186/1471-2407-14-993

McGrane JA; Butow PN; Sze M; Eisenbruch M; Goldstein D; King MT, 2014, 'Assessing the invariance of a culturally competent multi-lingual unmet needs survey for immigrant and Australian-born cancer patients: a Rasch analysis', Quality of Life Research, 23, pp. 2819 - 2830, http://dx.doi.org/10.1007/s11136-014-0717-5

Jefford M; Nolte L; Tsintziras S; Butow P; Sze M; Yiu D; Schofield P; Goldstein D; Price M, 2014, 'HOW IS POST-TREATMENT SURVIVORSHIP CONCEPTUALISED BY PEOPLE FROM DIFFERENT CULTURAL GROUPS?', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 10, pp. 158 - 158, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000346343700480&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wang X; Goldstein D; Crowe PJ; Yang JL, 2014, 'Impact of STAT3 inhibition on survival of osteosarcoma cell lines', Anticancer Research, 34, pp. 6537 - 6545

McGrane J; Butow P; Sze M; Eisenbruch M; Goldstein D; King M, 2014, 'Assessing the Invariance of a Culturally Competent Multi-lingual Unmet Needs Survey for Immigrant and Australian-born Cancer Patients: A Rasch Analysis', PSYCHO-ONCOLOGY, 23, pp. 153 - 153, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344003700220&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Hillman RJ; Garland SM; Gunathilake MPW; Stevens M; Kumaradevan N; Lemech C; Ward RL; Meagher A; McHugh L; Jin F; Carroll S; Goldstein D; Grulich AE; Tabrizi SN, 2014, 'Human papillomavirus (HPV) genotypes in an Australian sample of anal cancers.', Int J Cancer, 135, pp. 996 - 1001, http://dx.doi.org/10.1002/ijc.28730

Vernerey D; Hammel P; Paget-Bailly S; Huguet F; Van Laethem JL; Goldstein D; Glimelius B; Artru P; Moore M; André T; Mineur L; Chibaudel B; Louvet C; Bonnetain F, 2014, 'Prognosis Model for Overall Survival in Locally Advanced Pancreatic Cancer (LAPC): An Ancillary Study of the Lap 07 Trial', Annals of Oncology, 25, pp. ii105, http://dx.doi.org/10.1093/annonc/mdu193.2

McGrane JA; Butow PN; Sze M; Eisenbruch M; Goldstein D; King MT, 2014, 'Assessing the invariance of a culturally competent multi-lingual unmet needs survey for immigrant and Australian-born cancer patients: a Rasch analysis', Quality of Life Research, http://dx.doi.org/10.1007/s11136-014-0717-5

Goldstein D; El-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Macarulla T; Teixeira L; Tortora G; Van Laethem JL; Penenberg DN; Lu B; Romano A; Von Hoff DD, 2014, 'Analyses of updated overall survival (OS) and prognostic effect of neutrophil-to-lymphocyte ratio (NLR) and CA 19-9 from the phase III MPACT study of nab -paclitaxel ( nab -P) plus gemcitabine (Gem) versus Gem for patients (pts) with metastatic pancreatic cancer (PC).', Journal of Clinical Oncology, 32, pp. 4027 - 4027, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.4027

Tempero MA; Cardin DB; Biankin A; Goldstein D; Moore M; O'Reilly EM; Philip AP; Riess H; Macarulla T; Yung L; Wei X; Lu B, 2014, 'APACT: A phase 3 randomized, open-label, multicenter trial evaluating the use of adjuvant nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with surgically resected ductal pancreatic adenocarcinoma (PDA).', JOURNAL OF CLINICAL ONCOLOGY, 32, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.tps4162

Reichardt P; Demetri GD; Gelderblom H; Rutkowski P; Im S-A; Gupta S; Kang Y-K; Schoffski P; Schuette J; Soulieres D; Blay J-Y; Goldstein D; Fly KD; Huang X; Corsaro M; Lechuga M; Martini J-F; Heinrich MC, 2014, 'Correlation of KIT and PDGFRA mutational status with clinical benefit in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU) in a worldwide treatment-use (TU) trial.', Journal of Clinical Oncology, 32, pp. 10549 - 10549, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.10549

Huguet F; Hammel P; Vernerey D; Goldstein D; Van Laethem JL; Glimelius B; Spry N; Paget-Bailly S; Bonnetain F; Louvet C, 2014, 'Impact of chemoradiotherapy (CRT) on local control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study.', Journal of Clinical Oncology, 32, pp. 4001 - 4001, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.4001

Vernerey D; Hammel P; Paget-Bailly S; Huguet F; Van Laethem JL; Goldstein D; Glimelius B; Artru P; Moore M; Andre T; Mineur L; Chibaudel B; Louvet C; Bonnetain F, 2014, 'Prognosis model for overall survival in locally advanced pancreatic cancer (LAPC): An ancillary study of the LAP 07 trial.', JOURNAL OF CLINICAL ONCOLOGY, 32, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.4024

Davis ID; Long A; Martin A; Espinoza D; Yip S; Thompson JF; Kichenadasse G; Harrison M; Lowenthal RM; Pavlakis N; Azad A; Kannourakis G; Steer C; Goldstein D; Shapiro J; Stockler MR, 2014, 'EVERSUN: A PHASE 2 TRIAL OF EVEROLIMUS ALTERNATING WITH SUNITINIB AS FIRST-LINE THERAPY FOR ADVANCED RENAL CELL CARCINOMA (ANZUP TRIAL 0901)', EUROPEAN JOURNAL OF CANCER, 50, pp. E68 - E69, http://dx.doi.org/10.1016/j.ejca.2014.03.255

Back to profile page